Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).
Multiple Myeloma|Renal Insufficiency
DRUG: Carfilzomib
Clearance (CL) of Carfilzomib on Day 1 of Cycle 1, Plasma concentrations of carfilzomib was determined by a validated liquid chromatography tandem mass spectrometry (LC MS/MS) method. The lower limit of quantitation (LLOQ) was 0.300 ng/mL. Concentration values that were below the LLOQ (BLQ) were set to zero. Pharmacokinetic (PK) parameters were calculated from the individual plasma concentrations of carfilzomib using a noncompartmental method., Cycle 1, Day 1 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.
Clearance (CL) of Carfilzomib on Day 15 of Cycle 1, Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.|Clearance (CL) of Carfilzomib on Day 15 of Cycle 2, Cycle 2, Day 15, before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.|Maximum Observed Plasma Concentration of Carfilzomib on Day 1 of Cycle 1, Cycle 1, Day 1, before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.|Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 1, Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.|Maximum Observed Plasma Concentration of Carfilzomib on Day 15 of Cycle 2, Cycle 2, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.|Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 1 of Cycle 1, Cycle 1, Day 1, before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.|Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 1, Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.|Area Under the Plasma Curve Extrapolated to Infinity (AUCinf) for Carfilzomib on Day 15 of Cycle 2, Cycle 2, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.|Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 1 of Cycle 1, Cycle 1, Day 1 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.|Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 1, Cycle 1, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.|Area Under the Concentration Time Curve to the Last Measurable Concentration (AUClast) for Carfilzomib on Day 15 of Cycle 2, Cycle 2, Day 15 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.|Percentage of Carfilzomib Excreted Via Renal Elimination on Day 1 of Cycle 1, The percentage of carfilzomib excreted in urine was calculated as the total amount excreted over 24 hours/dose., Cycle 1, Day 1, 0-5 and 5-24 hours post-dose|Percentage of Carfilzomib Excreted Via Renal Elimination on Day 15 of Cycle 1, The percentage of carfilzomib excreted in urine was calculated as the total amount excreted over 24 hours/dose., Cycle 1, Day 15, 0-5 and 5-24 hours post-dose|Percentage of Carfilzomib Metabolites Excreted Via Renal Elimination on Day 1 of Cycle 1, The percentage of the metabolites of carfilzomib (PR-389/M14 and PR-413/M15) excreted in urine was calculated as the total amount excreted over 24 hours/dose., Cycle 1, Day 1, 0-5 and 5-24 hours post-dose|Percentage of Carfilzomib Metabolites Excreted Via Renal Elimination on Day 15 of Cycle 1, The percentage of the metabolites of carfilzomib (PR-389/M14 and PR-413/M15) excreted in urine was calculated as the total amount excreted over 24 hours/dose., Cycle 1, Day 15, 0-5 and 5-24 hours post-dose|Plasma Protein Binding (PPB) of Carfilzomib, The plasma protein binding (PPB) of carfilzomib in plasma samples was determined using a rapid equilibrium dialysis (RED) device. Data are averages of the 3 time points (Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 15)., End of injection and 5 minutes post-dose on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 15|Overall Response Rate (ORR), ORR is defined as the percentage of participants with a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per the International Uniform Response Criteria for Multiple Myeloma.

sCR: CR as defined below plus normal serum free light chain (sFLC) ratio and absence of clonal plasma cells in bone marrow by immunohistochemistry or immunofluorescence; CR: absence of M-protein in serum and urine confirmed by immunofixation and \< 5% plasma cells in the bone marrow; VGPR: serum and urine M-proteins detectable by immunofixation, but not by electrophoresis or a ≥ 90% reduction in serum M-protein from baseline, plus a urine M-protein level of \< 100 mg/24 hours; PR: reduction of M-protein in serum of ≥ 50% and in urine of ≥ 90% from baseline. If serum and urine M-protein were not measureable at baseline, a ≥ 50% decrease in the difference between involved and uninvolved sFLC levels from baseline., From first dose until 30 days after the last dose; median duration of treatment across all groups was 121 days.|Clinical Benefit Rate (CBR), Clinical benefit rate is defined as the percentage of participants whose best response was sCR, CR, VGPR, PR, or minimal response (MR), where MR is defined by the European Group for Blood and Marrow Transplant (EBMT) criteria as a reduction of M-protein in serum of 25% to 49% and in urine of 50% to 89% from baseline, maintained for at least 6 weeks., From first dose until 30 days after the last dose; median duration of treatment across all groups was 121 days.|Duration of Response, Duration of Response is defined as the time from first evidence of PR or better to confirmation of disease progression or death.

Progressive disease was defined as any of the following:

* An increase of more than 25% from nadir in any one of the following:

  * M-protein in serum (the absolute increase had to be ≥ 0.5 g/dL);
  * Urine (the absolute increase had to be ≥ 200 mg/24 hours);
  * The difference between involved and uninvolved sFLC (the absolute increase in the concentration of involved light chain had to be \> 10 mg/dL);
  * ≥ 10% bone marrow infiltration by plasma cells;
* Increased size of pre-existing bone lesions or plasmacytomas or new bone lesions or plasmacytomas.

Median duration of response was estimated using the Kaplan-Meier method., Participants were followed for disease progression for up to 2 years.|Time to Progression (TTP), Time to Progression is defined as the time from first dose of carfilzomib to disease progression. Median TTP was estimated using Kaplan-Meier methods., Participants were followed for disease progression for up to 2 years.
The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).